Premium
Smoking‐cessation treatments generally safe for patients with psychiatric disorders
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30435
Subject(s) - varenicline , bupropion , medicine , smoking cessation , anxiety , adverse effect , psychiatry , nicotine , mood , mood disorders , depression (economics) , nicotine patch , alternative medicine , pathology , economics , macroeconomics , placebo
A secondary analysis of the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) has concluded that varenicline, bupropion, and transdermal nicotine patch are all well‐tolerated in the subset of patients with psychotic, anxiety, and mood disorders. The analysis found no significant between‐group differences in neuropsychiatric adverse events based on treatment offered or patients' psychiatric diagnosis.